NRAS and melanoma: To test the role of BFL-1 in sensitivity of melanoma cells to BH3-mimetic drugs, we deleted BCL2A1 in three BRAF mutant melanoma cells (M14 and UACC257 show high BFL-1 expression; LOXIMVI show medium BFL-1 expression) and one NRAS mutant cell (SKMEL30 show high BFL-1 expression) by using our inducible CRISPR/Cas9 platform [14].